celsunax
pinax pharma gmbh - ioflupane (123i) - radionuclide imaging; dementia; movement disorders - diagnostikos radiofarmaciniai preparatai - Šis vaistas yra skirtas tik diagnostikai. celsunax is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:in adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. celsunax is unable to discriminate between parkinson's disease, multiple system atrophy and progressive supranuclear palsy. suaugusių pacientų, padėti atskirti tikėtina demencija su lewy įstaigos nuo alzheimerio ligos. celsunax is unable to discriminate between dementia with lewy bodies and parkinson’s disease dementia.
traslor
zakłady farmaceutyczne polpharma s.a. - travoprostas - akių lašai (tirpalas) - 40 µg/ml - travoprost
kapruvia
vifor fresenius medical care renal pharma france - difelikefalin - pruritus - visi kiti gydomieji produktai - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.
veregen
nordic pharma s.r.o. - Žaliosios arbatos lapų ekstraktas, rafinuotas (24-56:1) - tepalas - 100 mg/g - sinecatechins
ghryvelin (previously macimorelin aeterna zentaris)
atnahs pharma netherlands b.v. - macimorelin acetatas - diagnostikos metodus, endokrininės sistemos - macimorelin - Šis vaistas yra skirtas tik diagnostikai. ghryvelin is indicated for the diagnosis of growth hormone deficiency (ghd) in adults.
sigletic
zakłady farmaceutyczne polpharma s.a. - sitagliptinas - plėvele dengtos tabletės - 25 mg - sitagliptin
sigletic
zakłady farmaceutyczne polpharma s.a. - sitagliptinas - plėvele dengtos tabletės - 50 mg - sitagliptin
sigletic
zakłady farmaceutyczne polpharma s.a. - sitagliptinas - plėvele dengtos tabletės - 100 mg - sitagliptin
onureg
bristol-myers squibb pharma eeig - azacitidinas - leukemija, mieloidas, ūmus - antinavikiniai vaistai - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
azacitidine auxilia
auxilia pharma oÜ - azacitidinas - milteliai injekcinei suspensijai - 25 mg/ml - azacitidine